Markers for the progression of IgA nephropathy

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F16%3A10327389" target="_blank" >RIV/00064165:_____/16:10327389 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11110/16:10327389

Result on the web

<a href="http://dx.doi.org/10.1007/s40620-016-0299-0" target="_blank" >http://dx.doi.org/10.1007/s40620-016-0299-0</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s40620-016-0299-0" target="_blank" >10.1007/s40620-016-0299-0</a>

Result language

angličtina

Original language name

Markers for the progression of IgA nephropathy

Original language description

We have summarized the latest findings on markers for progression of immunoglobulin A (IgA) nephropathy (IgAN), the most common primary glomerulonephritis with a high prevalence among end-stage renal disease (ESRD) patients. The clinical predictors of renal outcome in IgAN nephropathy, such as proteinuria, hypertension, and decreased estimated glomerular filtration rate (eGFR) at the time of the diagnosis, are well known. The Oxford classification of IgAN identified four types of histological lesions (known as the MEST score) associated with the development of ESRD and/or a 50 % reduction in eGFR. In addition, the role of genetic risk factors associated with IgAN is being elucidated by genome-wide association studies, with multiple risk alleles described. Recently, biomarkers in serum (galactose-deficient IgA1, IgA/IgG autoantibodies against galactose-deficient IgA1, and soluble CD 89-IgA complexes) and urine (soluble transferrin receptor, interleukin-6/epidermal growth factor ratio, fractalkine, laminin G-like 3 peptide, kappa light chains, and mannan-binding lectin) have been identified. Some of these biomarkers may represent candidates for the development of noninvasive diagnostic tests, that would be useful for detection of subclinical disease activity, monitoring disease progression, assessment of treatment, and at the same time circumventing the complications associated with renal biopsies. These advances, along with future disease-specific therapy, will be helpful in improving the treatment effectiveness, prognosis, and the quality of life in connection with IgAN.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

EB - Genetics and molecular biology

OECD FORD branch

—

Project

<a href="/en/project/LH15168" target="_blank" >LH15168: Factors affecting the course of IgA nephropathy – the most common primary glomerulonephritis.</a><br>

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2016

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Journal of Nephrology

ISSN

1121-8428

e-ISSN

—

Volume of the periodical

29

Issue of the periodical within the volume

4

Country of publishing house

IT - ITALY

Number of pages

7

Pages from-to

535-541

UT code for WoS article

000379768200010

EID of the result in the Scopus database

2-s2.0-84978646600